In this issue of Blood, Guida et al reveal a novel role for the Toll-like receptors (TLR)2 and TLR6 in mediating hypoferremia in response to inflammatory stimuli. 1 T he development of hypoferremia, ie, a decrease in circulating iron levels, is a common response to systemic infections and inflammatory conditions. Hypoferremia in these disorders results from the sequestration of iron within macrophages, a response that may have evolved as a host defense mechanism to reduce iron availability to pathogens. 2 However, hypoferremia also restricts iron availability to erythroid precursors, and if prolonged, may contribute to the development of the anemia of inflammation.
Previous studies have implicated hepcidin, a circulating peptide hormone produced primarily by hepatocytes, as a central mediator of the hypoferremic response to inflammatory stimuli. Hepcidin synthesis is induced by several cytokines, including interleukin (IL)-6, IL-1, and IL-22, as well as bacterial lipopolysaccharide (LPSs).
2 Hepcidin binds to ferroportin, an iron exporter primarily expressed in cell types that process large amounts of iron, including hepatic and splenic macrophages (which recycle iron from senescent erythrocytes), duodenal enterocytes (which absorb dietary iron), and hepatocytes (which serve as the major site of iron storage). Because hepcidin binding triggers the internalization and degradation of ferroportin, hepcidin limits the export of iron into the circulation. Although hepatocytes serve as the major source of circulating hepcidin, hepcidin is also produced by other cell types, including macrophages, where it may contribute to the local regulation of iron fluxes.
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In the present study, Guida et al sought to identify novel genes that regulate ferroportinmediated iron export from cells. Using gene silencing by small interfering RNA-based knockdown technology in HeLa cells, the authors screened a large collection of protein kinases and related signaling molecules for the ability to modulate ferroportin expression levels. This screen identified TLR6 as a suppressor of ferroportin protein levels. 1 TLRs serve as key regulators of specific innate immune responses by recognizing microbe-specific molecular signatures. TLRs are single transmembrane spanning proteins expressed in both immune and nonimmune cells and are known to function as dimers. TLR6, the TLR identified in the present study, is known to heterodimerize with TLR2. 4 To test whether TLR6 signaling could alter ferroportin expression in macrophages, Guida et Next, the authors examined whether administration of TLR ligands to mice could induce acute changes in systemic iron homeostasis. Similar to injection with LPS, injection of wild-type mice with FSL1 reduced ferroportin expression in the liver and spleen, promoted iron sequestration in these organs, and induced hypoferremia within 3 hours. However, in contrast to LPS, injection of FSL1 failed to increase hepcidin mRNA in either liver or spleen of wild-type mice. Importantly, FSL1 injection was also effective in acutely lowering hepatic and splenic ferroportin expression and plasma iron levels in mice harboring a mutant form of ferroportin that is rendered insensitive to hepcidin due to an amino acid substitution (C326S) in the hepcidin-binding domain. Administration of Pam3CSK4, a synthetic ligand recognized by TLR2, to wild-type mice as well as to the hepcidin-insensitive ferroportin mutant mice, produced changes in ferroportin expression and plasma iron levels similar to those induced by FSL1, demonstrating conservation of the response across different TLR ligands.
Based on their novel findings, Guida et al 1 propose a model whereby FSL1 binds to TLR2/6, which in turn downregulates ferroportin, resulting in hypoferremia by a mechanism that is hepcidin independent (see figure) . Interestingly, a recent study of hepcidin-knockout mice also suggested that the hypoferremic response to inflammatory stimuli may not be entirely hepcidin dependent, as these mice remained capable of responding to LPS injection with a moderate, but significant, reduction in plasma iron levels.
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A model for TLR2/6-mediated hypoferremia. Binding of specific TLR ligands to the Toll-like receptors TLR2 and TLR6 downregulates the expression of the cellular iron exporter ferroportin in reticuloendothelial macrophages. As a result, iron that has been recycled from senescent red blood cells fails to be exported into the plasma, promoting the development of hypoferremia.
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For personal use only. Several approaches that antagonize the hepcidin-ferroportin interaction are under investigation as potential therapies for iron-restricted anemias, including reducing hepcidin production, neutralizing the hepcidin peptide, blocking hepcidin binding to ferroportin, and enhancing ferroportin membrane expression. 10 Future study of the hepcidin-independent role of TLR2/6 to the development of hypoferremia may be informative in elucidating additional strategies that might be used for treatment of iron-restricted anemias.
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